1,3-β-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia

Clinical Infectious Diseases

Volumn 46, Issue 6, 2008, Pages 878-885

  Senn, Laurence ^a   Robinson, James Owen ^a   Schmidt, Sabine ^a   Knaup, Marlies ^a   Asahi, Nobuo ^b   Satomura, Shinji ^b   Matsuura, Shuuji ^b   Duvoisin, Bertrand ^a   Bille, Jacques ^a   Calandra, Thierry ^a   Marchetti, Oscar ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b FUJIFILM Wako Pure Chemical Corporation   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 1,3 GLUCAN; BETA GLUCAN; BETA-1,3-D-GLUCAN; FUNGUS ANTIGEN; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; ADULT; AGED; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CANDIDA TROPICALIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FUNGAL COLONIZATION; HUMAN; INVASIVE CANDIDIASIS; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; ROC CURVE; SENSITIVITY AND SPECIFICITY; ACUTE GRANULOCYTIC LEUKEMIA; BLOOD; CANDIDIASIS; EVALUATION; FUNGEMIA; LYMPHATIC LEUKEMIA; MIDDLE AGED; MYCOSIS; PREDICTION AND FORECASTING;

ADULT; AGED; ANTIGENS, FUNGAL; ASPERGILLOSIS; BETA-GLUCANS; CANDIDIASIS; FEMALE; FUNGEMIA; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYCOSES; NEUTROPENIA; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY;

EID: 40749151917     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/527382     Document Type: Article

References (40)

1. EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989; 86:668-72.
2. Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43:25-31.
3. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356:348-59.
4. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356:335-47.
5. de Pauw BE, Donnelly JP. Prophylaxis and aspergillosis - has the principle been proven? N Engl J Med 2007; 356:409-11.
6. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34:730-51.
7. de Pauw BE, Sable CA, Walsh TJ, et al. Impact of alternate definitions of fever resolution on the composite endpoint in clinical trials of empirical antifungal therapy for neutropenic patients with persistent fever: analysis of results from the Caspofungin Empirical Therapy Study. Transpl Infect Dis 2006; 8:31-7.
8. Walsh TJ, Lee J, Dismukes WE. Decisions about voriconazole versus liposomal amphotericin B. N Engl J Med 2002; 346:1499.
9. Mennink-Kersten MA, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 2004; 4:349-57.
10. de Pauw BE. Between over- and undertreatment of invasive fungal disease. Clin Infect Dis 2005; 41:1251-3.
11. Segal BH, Almyroudis NG, Battiwalla M, et al. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin Infect Dis 2007; 44:402-9.
12. Maertens J, Verhaegen J, Lagrou K, Van EJ, Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001; 97:1604-10.
13. Herbrecht R, Letscher-Bru V, Oprea C, et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 2002; 20:1898-906.
14. Prella M, Bille J, Pugnale M, et al. Early diagnosis of invasive candidiasis with mannan antigenemia and antimannan antibodies. Diagn Microbiol Infect Dis 2005; 51:95-101.
15. Sendid B, Caillot D, Baccouch-Humbert B, A et al. Contribution of the Platelia Candida-specific antibody and antigen tests to early diagnosis of systemic Candida tropicalis infection in neutropenic adults. J Clin Microbiol 2003; 41:4551-8.
16. Weisser M, Rausch C, Droll A, et al. Galactomannan does not precede major signs on a pulmonary computerized tomographic scan suggestive of invasive aspergillosis in patients with hematological malignancies. Clin Infect Dis 2005; 41:1143-9.
17. Miyazaki T, Kohno S, Mitsutake K, et al. Plasma (1→3)-β- D-glucan and fungal antigenemia in patients with candidemia, aspergillosis, and cryptococcosis. J Clin Microbiol 1995; 33:3115-8.
18. Mori T, Ikemoto H, Matsumura M, et al. Evaluation of plasma (1→3)-β-D-glucan measurement by the kinetic turbidimetric Limulus test, for the clinical diagnosis of mycotic infections. Eur J Clin Chem Clin Biochem 1997; 35:553-60.
19. Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1→3) β-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005; 41:654-9.
20. Pazos C, Ponton J, Del PA. Contribution of (1→3)-β-D- glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol 2005; 43:299-305.
21. Odabasi Z, Mattiuzzi G, Estey E, et al. β-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004; 39:199-205.
22. Kawazu M, Kanda Y, Nannya Y, et al. Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1→3)-β-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. J Clin Microbiol 2004; 42:2733-41.
23. Pickering JW, Sant HW, Bowles CA, Roberts WL, Woods GL. Evaluation of a (1→3)-β-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2005; 43:5957-62.
24. Kanda H, Kubo K, Hamasaki K, et al. Influence of various hemodialysis membranes on the plasma (1→3)-β-D-glucan level. Kidney Int 2001; 60:319-23.
25. Usami M, Ohata A, Horiuchi T, Nagasawa K, Wakabayashi T, Tanaka S. Positive (1→3)-β-D-glucan in blood components and release of (1→3)-β-D-glucan from depth-type membrane filters for blood processing. Transfusion 2002; 42:1189-95.
26. Ogawa M, Hori H, Niiguchi S, Azuma E, Komada Y. False-positive plasma (1→3)-β-D-glucan test following immunoglobulin product replacement in an adult bone marrow recipient. Int J Hematol 2004; 80:97-8.
27. Mennink-Kersten MA, Warris A, Verweij PE. 1,3-β-D-glucan in patients receiving intravenous amoxicillin-clavulanic acid. N Engl J Med 2006; 354:2834-5.
28. Marty FM, Lowry CM, Lempitski SJ, Kubiak DW, Finkelman MA, Baden LR. Reactivity of (1→3)-β-D-glucan assay with commonly used intravenous antimicrobials. Antimicrob Agents Chemother 2006; 50:3450-3.
29. Calandra T, Bille J, Schneider R, Mosimann F, Francioli P. Clinical significance of Candida isolated from peritoneum in surgical patients. Lancet 1989; 2:1437-40.
30. Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient: report of a consensus panel. J Infect Dis 1990; 161:397-401.
31. Cometta A, Kern WV, De BR, et al. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis 2003; 37:382-9.
32. Feld R, DePauw B, Berman S, Keating A, Ho W. Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial. J Clin Oncol 2000; 18:3690-8.
33. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34:7-14.
34. Moro H, Tsukada H, Ohara T, et al. Clinical evaluation of performance of a new diagnostic method for deep mycosis by measuring β-glucan concentration in the blood [in Japanese]. Kansenshogaku Zasshi 2003; 77:219-26.
35. Marr KA, Balajee SA, McLaughlin L, Tabouret M, Bentsen C, Walsh TJ. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 2004; 190:641-9.
36. Odabasi Z, Paetznick VL, Rodriguez JR, Chen E, McGinnis MR, Ostrosky-Zeichner L. Differences in beta-glucan levels in culture supernatants of a variety of fungi. Med Mycol 2006; 44:267-72.
37. de Pauw BE, Patterson TF. Should the consensus guidelines'specific criteria for the diagnosis of invasive fungal infection be changed? Clin Infect Dis 2005; 41( Suppl 6):S377-80.
38. Upton A, Leisenring W, Marr KA. (1→3) β -D-glucan assay in the diagnosis of invasive fungal infections. Clin Infect Dis 2006; 42:1054-6.
39. Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005; 41:1242-50.
40. Alexander BD, Pfaller MA. Contemporary tools for the diagnosis and management of invasive mycoses. Clin Infect Dis 2006; 43(Suppl 1):S15-27.